Current Stem Cell Reports

, Volume 4, Issue 4, pp 327–337 | Cite as

Mini Review: Application of Human Mesenchymal Stem Cells in Gene and Stem Cells Therapy Era

  • Ruixia Deng
  • Anna Hing Yee Law
  • Jiangang Shen
  • Godfrey Chi-Fung ChanEmail author
Genome Editing (SN Waddington and HC O'Neill, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Genome Editing


Purpose of Review

Mesenchymal stem cells (MSCs) have abilities of self-renewal and multi-lineage differentiation. MSCs can evade immune rejection following allogeneic transplantation setting due to their downregulation of HLA Class II antigen. Therefore, we review the current understanding of using MSCs or MSC-conditioned media as treatment for various diseases.

Recent Findings

(1) MSCs regulate the balance of Th17/Treg cells in autoimmune disease models, which is associated with complex interactions among different pro- or anti-inflammation cytokines. (2) With the nature of MSCs migrating to multiple tissues under various homing signals, we also found MSCs are widely used as cell vehicles for gene or chemokine delivery.


MSCs or MSC-conditioned media therapies have been explored with advanced techniques. However, it still requires further investigations on (1) how MSCs respond to various microenvironments and (2) how to isolate, purify and expand enough MSCs ex vivo.


Mesenchymal stem cells Cell therapy Autoimmune Paracrine Genetic modification Delivery tool 


In 1968, mesenchymal stem cells (MSCs) were first derived, by Friedenstein et al., from bone marrow [1]. MSCs are historically considered as hematopoietic supporting cells that secrete growth factors and relevant cytokines. They are self-renewing multipotent progenitor cells with the potential to differentiate into cells of mesodermal origin, such as osteoblasts, adipocytes, and chondroblasts under standardized in vitro conditions. MSCs are plastic-adherent cells that express specific cell-surface molecules CD105+, CD73+, and CD90+ and do not express CD11b-, CD79a-, CD19- or human leukocyte antigen (HLADR-) [2]. They have been applied clinically for tissue repair and immune modulation in both pre-clinical and clinical studies due to their differentiation and immunosuppressive effects [3, 4, 5, 6] (Fig. 1). Here, we have summarized recent clinical translational studies of MSCs in two parts: (i) the application of primary MSCs as direct cellular therapy and (ii) the use of genetic modified MSCs as vehicles for gene therapy.
Fig. 1

The schematic diagram of roles of MSCs in direct and indirect applications. MSCs can be directly applied to inflammatory microenvironments, especially the Treg/Th17 modulated autoimmune diseases via either cell to cell responses or paracrine effects. On the other hand, MSCs can also be used as a vehicle to deliver therapeutic proteins in treatments for MS, HD, and cancer. MSCs mesenchymal stem cells, Treg T regulatory cells, Th17 T helper 17 cells, MS multiple sclerosis, HD Huntington’s disease

Part I

Applications of Primary MSCs

MSCs play an important role in immune regulation. They modulate functions of a wide spectrum of immune cells including lymphocytes, dendritic cells and natural killer cells. They exert their role both by direct contact and by secretion of anti-inflammatory soluble factors mostly via extracellular vesicles. To examine the immune suppression mechanisms of MSCs, we have studied various in vivo models, including graft versus host disease [7], murine collagen-induced arthritis [8] and bleomycin-induced pulmonary fibrosis in humanized mice [9••]. Researchers have been investigating the possibility of using MSCs as a biological drug to treat diseases including autoimmune diseases and neurodegenerative diseases, due to their immune-suppressive and regenerative potential. Our group has conducted clinical trials (IRB: UW 13-154) to investigate the therapeutic effects of MSCs for the treatment of graft versus host disease (GVHD) and the underlying mechanisms of suppressing the secretion of RANTES, CCL3, CXCL9, CCR5 and CXCR3 after 6 days after T cell transplantation in GVHD mouse model [7]. Immune-suppression effect of MSCs can also reduce the organ damages and inflammations in autoimmune diseases with unclear causes, a condition in which the immune system mistakenly attacks the owner’s body. MSCs act as therapeutic cells for autoimmune diseases, such as systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), multiple sclerosis (MS) and rheumatoid arthritis (RA). Here, we addressed the updated applications of MSCs on patients or mouse models of SLE, MS and IBD [10].

Systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is an incurable multi-organ systemic autoimmune disorder. Research has been carried out to investigate the underlying therapeutic mechanisms of MSCs in refractory SLE patients. A clinical study using allogeneic donor MSC transplantation to treat 30 patients with active refractory SLE showed they can balance the interaction between T regulatory (Treg) and Th17 cells. Upon infusion of MSCs, Treg cells were upregulated, while Th17 cells were suppressed; the processes were mediated through the secretion of transforming growth factor beta (TGF-β) and prostaglandin E2 (PGE2) [10]. In another study by Chen et al., MSCs increased the level of Treg cells in SLE patients, partly through soluble human leukocyte antigen sHLA-G [11]. On the other hand, by transferring functional mitochondria, MSCs also downregulated autophagy and apoptosis in T cells from SLE patients [12]. In a mouse model of SLE, CCL2 from transplanted MSCs was found to play a role in suppressing autoreactive T cells. CCL2 enhances T cell VCAM-1 expression and maintains cellular contacts, inhibiting IFN-γ production in turn [13].

Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is a chronic disease that causes prolonged inflammation in the gastrointestinal tract. Systemic infusion of MSCs ameliorated the severity of colitis in a trinitrobenzene sulfonic acid-induced colitis mouse model, through suppressing inflammatory factors including IL-2, TNF-α, IFN-γ, T-bet, IL-6, IL-17, RORγt, and Th1-Th17-driven autoimmune responses [14]. While, in dextran sulfate sodium-induced IBD models [15, 16•], injection of MSCs increased the expression of IL-10 but suppressed the inflammatory cytokines including TNF-α, IL-6, IL-1β, IP-10, MCP-1, IFN-γ and also 15-LOX-1 [15]. Reductions of macrophage and dendritic cell infiltration in the intestinal lamina propria upon MSC treatment were also demonstrated [16•].

In order to further improve the therapeutic efficacy of MSCs in IBD, preconditioning of MSCs with Toll-like receptor (TLR-3) priming effectively improved clinical parameters and decreased pathological severity in colitis mouse models [17, 18]. The therapeutic enhancing effects were found to be mediated through the TLR3-activated Notch-1 signaling pathway [17].

Multiple Sclerosis

Multiple sclerosis (MS) is an autoimmune neurodegenerative disease of the central nervous system in which the myelin sheath is damaged, leading to dysfunction of the brain and spinal cord. MSCs from different sources have been demonstrated to have immune modulatory functions and alleviate the symptoms in experimental autoimmune encephalomyelitis (EAE) mouse model [19, 20, 21•].

In delineating the mechanisms involved under MSC treatment, Anderson et al. showed that MSCs alleviated the disease severity by suppressing both the autoantigen-specific T cells and dendritic cells in EAE mice [22]. Tafreshi et al. showed that MSCs maintained the inactive form of GSK3-β in neurons, which ameliorated the symptoms in EAE mice [23].

Several studies were carried out aiming to improve the efficacy of MSC treatment in MS. Dang et al., which showed that autophagy is involved in regulating the therapeutic effect of MSCs in EAE mice and inhibition of the autophagy pathway by knocking down Beclin-1 significantly improved the treatment outcome through upregulating the immunosuppressive effect of MSCs [24•]. Treating MSCs with the small molecule resveratrol augments the therapeutic efficacy of MSCs in EAE mice. This treatment suppresses pro-inflammatory cytokines including IFN-γ and TNF-α and increases anti-inflammatory cytokines IL-4 and IL-10 [25]. Combination therapy of MSCs and nicotine significantly reduced the cumulative disease disability, which could be attributed to the reduced IL-17 and TNF-α levels [26].

Cell-Free Therapeutic Alternative

Instead of using the MSCs directly, recent studies have demonstrated that soluble factors and extracellular vesicles from MSCs may have similar therapeutic potential particularly for their immunomodulatory properties. Preclinical studies have been carried out to test the therapeutic effects of the secreted factors from MSCs in various disease models.

Conditioned medium from hypoxia-conditioned adipose-derived MSCs significantly accelerated wound healing by suppressing inflammation and promoting neovascularization and re-epithelialization in a gastric mucosal injury mouse model [27]. In an in vivo EAE experiment, it was shown that skin-derived MSCs produced soluble TNF receptor 1, which antagonized TNF-α and in turn suppressed Th17 cell differentiation. This action ameliorated the development of EAE in mice [28]. In a mouse model of thioacetamide-induced acute liver injury, although overall survival rate of the mice was not improved, conditioned-media from bone marrow-derived MSCs and embryonic stem cell-derived MSCs improved the biochemical and histopathological parameters of the injured livers, which provided support to the therapeutic potential of MSC secretome in acute hepatic failure [29]. With application in allogeneic hematopoietic stem cell transplantation, extracellular vesicles released from MSCs reduced the manifestations of acute graft-versus-host disease and the associated histologic changes. Further investigation showed that the frequencies and absolute numbers of CD3+CD8+ T cells, serum levels of IL-2, TNF-α, and IFN-γ were lowered, but serum IL-10 level was increased [30]. Systemic administration of MSC exosomes into rats with spinal cord injury significantly reduced lesion size and improved functional recovery. These protective effects were found to be mediated through reducing the pro-apoptotic and pro-inflammatory factors and upregulating the anti-apoptotic and anti-inflammatory proteins [31].

Part II

Genetic Modification of Mesenchymal Stem/Stromal Cells

With the advancement in biotechnology, scientists and clinical researchers are exploring new applications of genetically modified MSCs. Theoretically, after genetic engineering, MSCs should maintain most of their intrinsic properties with the addition of new functions, such as overexpression of specific proteins. It facilitates cell regeneration, tissue repair, cancer treatment, and immune modulation according to the genetic design. We summarized the recent published works in Table 1.
Table 1

Summary of genetic modifications of MSCs

Target tissue

MSC source

Modification Vehicle

Modified Gene

Brief Description

In vivo / in vitro




A nanocarrier of bioactive glass


Increased deposition of mineralized extracellular matrix

In vitro




Enhanced osteogenic differentiation

In vitro






Reduced inflammation and improves glucose tolerance in vivo

In vivo: obese diabetic mice






hFVIII protein or activity is undetectable in plasma but induced immune tolerance to hFVIII

In vivo: Hemophilia A/immunocompetent mice




Porcine FVIII

High expression of porcine FVIII

In vitro




Porcine FVIII

High expression of porcine FVIII ex vivo; In vivo: porcine FVIII from modified MSCs rapidly neutralized but sustained high level porcine FVIII from modified HSC

In vivo: Hemophilia A/immunocompetent mice






Created cardiac pacemaker cells

In vitro





MSC survival in the infarcted heart

In vivo: rat myocardial infarction (MI)





Improved components of the angiogenesis process under a hypoxic condition

In vitro





Modify MSC to be cardiac pacemaker cells

In vitro




Survivin (SVV)

Better prognosis for myocardial infarction (MI) by enhancing cellular survival

In vitro and In vivo(MI)





Enhanced cell survival, revascularization, and functional improvement

In vitro and In vivo (MI)



FuGENE HD transfection reagent

Sonic Hedgehog (Shh)

Improved their survival and angiogenic potential in the ischemic heart

For in vivo studies, acute myocardial infarction model was developed in Fisher-344 rats.

[44, 45]




Enhance survival rate of MSCs during transplantation

In vivo




TALEN-mediated AAVS1 site integration of VEGF

Precise site integration

In vivo: SCID mice; in rat myocardial infarction model






Enhanced neovascularization in hind limb ischemia

In vivo: injection of these cells into ischemic muscles of unilateral hindlimb ischemia C57BL6/J mice





Promoted neovascularization in ischemic tissues

In vitro




Overexpressing HIF-2a

RMSCs (HIF-2α) stimulated endothelial cell invasion under hypoxia; improves post-transplantation outcomes in a rat hindlimb ischemia model possibly by stimulating proangiogenic growth factors and cytokines

In vivo: a rat hindlimb ischemia model





Transduced MSCs with HGF by adenoviral vector

Enhance tissue repair in acute lung injury rat model

In vivo: rat ischemia/reperfusion model


Neural disease



CRISPR/Cas9 and mutant HTT

CRISPR/Cas9-mediated editing of the mutation site of the Huntingtin gene (HTT) to silence it

In vitro





Attenuated neuropathic pain

In vivo: 4th lumbar and L5 DRGs of adult allogeneic rats




BDNF and/or NGF

Increase in neurogenesis-like activity

In vivo: YAC 128 transgenic mice





Increase in neurogenesis-like activity

In vivo: immune-suppressed HD transgenic mice: YAC128 and R6/2.





Increase in neurogenesis-like activity

Plan to submit to FDA for clinical trial I





Transdifferentiate into Schwann cells

In vitro






Prolonged life span and enhanced angiogenic ability

In vitro





Improved human bone marrow-MSC quality

In vitro






MSCs migrated to injured and inflamed areas

In vivo: MDAMB231/Rluc tumor model




TRAIL-based TR3

MSCs migrated to tumor sites, triggering cancer cells apoptosis.

In vitro




Deletion of E1B19K gene or express TRAIL in oncolytic viruses

MSCs were applied as carrier cells for shielded virus delivery to tumors after ex vivo infection with oncolytic viruses

In vitro: Cancer cells




A single-chain antibody against EGFRvIII

Targeting of hMSCs to specific cell populations within tumors

In vitro





Induced hepatoma cell death

In vitro and In vivo (nude mice)




TNF-α and CD40L

Enhanced cancer therapy by triggering antitumour immune responses

In vivo: BALB/c mouse





MSC-based IFN-β therapy for prostate cancer lung metastasis

In vivo: immuno-competent mouse model of prostate cancer lung metastasis


Either naïve or genetically modified MSCs have been widely used in academic and clinical research for various indications. Primary human MSCs are precious and the expansion rate is slow with finite ex vivo life span. Therefore, human MSCs are engineered by expressing either hTERT to prolong the life span [58] or Nanog and Oct4 to improve stemness [59, 67].

At first, adenoviral, retroviral, and lipid vectors were used to engineer MSCs [35, 36, 68, 69, 70]. However, due to safety considerations, several non-viral transduction methods have been developed in recent years, including methods using nanoparticles, electroporation, and polymers (polyethylenimine) [71, 72, 73, 74]. A comparison between non-viral and viral vector methods on porcine MSCs shows that viral transduction has a higher efficiency but lower survival rate [75]. Besides optimizations of lentiviral vector and adeno-associated virus (AAV) methods, RNA viral vectors and new materials are increasingly popular in gene modification of MSCs [32, 76, 77, 78]. For examples, Sendai virus and a glass macromolecular carrier have been used in the past 5 years. There is a study using TALEN-genome editing to introduce the inducible VEGF gene cassette into a safe harbor genomic site of thuman umbilical cord blood-derived MSCs, resulting in enhanced angiogenesis in vivo [47]. Lenti-CRISPR/Cas9 gene editing of MSCs is also used for silencing the mutant Huntingtin gene [52]. A detailed discussion of various methodologies is outside the scope of this review but has been recently reviewed by Park [79••].

MSC as Delivery Vehicle in Immuno-Regulation

Owing to the unique homing ability of MSCs to many tissues, the therapeutic potential of using MSCs as delivery vehicle to treat various diseases, especially cancers, have been investigated. MSCs carrying an engineered suicide gene or drug-sensitive gene have been used in various cancer models, including pancreatic cancer [80], hepatocarcinoma [81], neuroblastoma [82], and brain metastatic melanomas [83]. On the other hand, with the immune tolerance property, MSCs have become a promising candidate in developing cell-based therapy. In a collagenase-induced osteoarthritis mouse model, MSCs overexpressing IL-10 were injected into the affected knee of the diseased mice and the results showed a significant reduction in activated CD4 and CD8 T cells resulting in reduced disease severity [84]. In a transient middle cerebral artery occlusion model, rats received MSCs overexpressing IL-10 after ischemia-reperfusion. This significantly reduced infarct volumes and improved motor function [85]. MSCs overexpressing IFN-β increased the Treg and IL-10 levels in EAE mice, while the IL-17 level was suppressed [86]. Neuroinflammation was also ameliorated in EAE mice when injected with IFN-β expressing MSCs [87]. While in another study, MSCs overexpressing IL-10 together with selectin ligands P-selectin glycoprotein ligand-1 (PSGL-1) and Sialyl-Lewisx (SLeX) were transplanted into EAE mice. MSCs homing to the inflamed spinal cord were significantly enhanced, and the therapeutic effect of the triple PSGL1/SLeX/IL-10 engineered MSCs was better than naïve MSCs [88].

Neurological Diseases

Brain-derived neurotrophic factor (BDNF), neurotrophin nerve growth factor (NGF) and Glial cell-derived neurotrophic factor (GDNF) are important for neuronal cells survival, maintenance and regeneration. These neurotrophic factors have been considered as potential therapeutics for neurodegeneration diseases, such as Parkinson’s, Alzheimer’s and Huntington’s diseases. Genetic modified MSCs are thought to be an ideal delivery tool for these therapeutic factors in neuro-repair [52, 55••, 56, 57, 89]. Isolated from either human donors, mice, or rats, MSCs can be programmed to heterogeneously secrete BDNF and/or NGF [55••, 56, 57] by using retroviral transduction. Those programmed MSCs can produce sustainable, effective specific growth factors and are capable of transdifferentiating into neuron-like cells, oligodendrocyte-like cells and Schwann cells in vitro. Huntington’s disease (HD) is caused by mutations in exon 1 of the huntingtin gene. Reduced BDNF expression due to the mutant huntingtin protein correlates with and is indicated to be the major cause for neurodegeneration in HD brain. MSCs engineered to secrete NGF or BDNF decreased striatal atrophy and reduced anxiety in HD transgenic YAC128 mice [54, 55••]. Currently, this approach has been submitted to FDA for a phase I clinical trial of MSC/BDNF in patients with HD [56]. Furthermore, MSC/BDNF is also considered for clinical studies of regeneration in traumatic brain injury, spinal cord, and peripheral nerve injury. MSCs transduced with GDNF can potentially attenuate neuropathic pain and inflammation in spinal cord injury models [53].

Tissue Repair and Regeneration

Ischemia heart disease (IHD) is the most common type of heart disease [90]. Preclinical studies of ischemic and non-ischemic cardiomyopathy employing MSC-based therapy have demonstrated MSCs’ properties of reducing fibrosis, stimulating angiogenesis, and cardiomyogenesis [91, 92, 93, 94]. However, low cell survival and engraftment rates have restricted MSC application in transplantations.

To achieve higher survival rate of transplanted MSCs, one approach is to directly overexpress proteins that promote cell survival, such as heat shock protein 27 (Hsp27) [39], heat shock protein 20 (Hsp20) [43], survivin (SVV) [42], and hBcl-xL [46] in MSCs before transplantation. Another method is to reduce hypoxia damage caused by ischemia. For example, genetic modification of MSCs by hypoxia-inducible factor 1 alpha (HIF-1α) overexpression improves the angiogenesis process under hypoxic condition [40]. Or alternatively, to increase oxygen delivery by enhancing angiogenesis, such as expressing vascular endothelial growth factor (VEGF) [47], and sonic hedgehog (Shh) [44, 45] in MSCs for delivery in vivo and in vitro. Overexpression of HIF-2α in MSCs stimulates endothelial cell invasion under hypoxia and improves blood perfusion and arteriogenesis [50]. MSCs with transduction of HIF-2α, prostacyclin synthase (PGIS) by adenoviral vector, or ephrin-B2 via nucleofection-enhanced neovascularization in hindlimb ischemia rat model [48, 49, 50].

Tissue damage often intensifies the inflammatory response. Hepatocyte growth factor (HGF) secreted by MSCs has immunosuppressive effects in vivo and in vitro [95]. Therefore, overexpressed HGF from MSCs can enhance tissue repair in an acute lung injury rat model [51] and skeletal muscle recovery in muscle injury model [51].

In proof-of-concept studies to develop substitutes for electronic pacemakers, MSCs were converted into cardiac pacemaker cells by transducing hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) [38] and hyperpolarization-activated cyclic nucleotide-gated channel 2 (HCN2) [41] genes using lentiviral vectors.


MSCs exist in many tissues and can migrate to various injury sites [96] including the tumor microenvironment. The tumor microenvironment is essential in supporting cancer cell growth including invasion, proliferation, and dissemination [97]. Numerous reports have described that MSCs are ambivalent to be either pro- or anti-tumorigenic. The roles of MSCs involved in the tumor microenvironment are complex and unclear. We have focused on how genetically modified MSCs can improve their capability in (i) migration to cancer cells [60, 63], (ii) triggering cancer cells death [61, 62, 64], and (iii) stimulating antitumor immune response [65, 66]. Another excellent review on the role of MSCs in cancer was written by Sage et al. [98].

Our group found that the interaction between SDF1 and its receptor CXCR4 plays an important role in migration of MSCs [99, 100]. MSCs genetically modified by retroviral transduction to overexpress CXCR4 improves MSC homing and migration to tumor sites [60, 101]. Another effort to enhance tumor-specific homing of MSCs is to express a transmembrane single-chain antibody against EGFRvIII a target protein on glioblastoma multiforme (GBM) cell surface [63]

Most conventional anti-cancer treatments aim to kill cancer cells mainly by targeting at rapidly proliferating cells. Such an approach is barely satisfactory because of significant off-target effects on healthy tissues or cells. With capability of migrating to tumor sites, we may induce MSCs as an anti-cancer armamentarium in cancer-associated microenvironment. Zhang et al. genetically modified MSCs to release adenoviral particles coding apoptin targeting hepatoma cells in vitro and in vivo [64]. Apoptin, a small protein from chicken anemia virus, resides in the cytoplasm of normal cells but translocates into the nucleus of cancer cells. There, it accumulates and triggers a p53-independent mitochondrial death. This study successfully utilizes MSCs as a novel in vivo drug delivery vehicle to the tumor site and inhibited tumor growth. With a similar idea, Hammer et al. engineered modified MSCs as carrier cells of adenoviruses to serve as oncolytic virus in vitro. In this study, they optimized adenoviral production from MSCs by deletion of the anti-apoptotic viral gene E1B19K or expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in the engineered oncolytic adenoviruses (OAds) [62]. Adenovirus transduced MSCs secreting a TRAIL-based anti-cancer therapy showed benefit in MUC16-expressing ovarian cancer cells [61]. However, further investigations and evaluations in an in vivo tumor xenograft mouse model are required.

The immune system plays a key role in controlling cancer initiation and progression. Increasing evidence indicates the immunosuppressive nature of the local environment in tumor. MSCs are continuously recruited to and become an integral component of the tumor microenvironment. Although the roles of MSCs in tumor remain elusive, they were modified to trigger antitumor immune responses by expressing TNF-α/CD40L [65] or IFN-β [66] for cancer therapy. These studies yielded satisfactory outcomes with increased antitumor immune response noted. Such approach also increased the experimental mice lifespan or decreased in vivo tumor volume.

Other Applications

In 1998, Evans and Morgan used a retroviral vector to transduce murine bone marrow with human coagulation factor VIII [35]. The method of retroviral vector-mediated gene transfer into hematopoietic progenitors in the mouse achieved > 30% efficiency. However, they did not identify the cell populations in the transduced murine bone marrow. Both hematopoietic progenitors and mesenchymal stromal cells were likely involved. This approach can serve as a promising tool for the delivery of secreted proteins. MSCs have been genetically modified to express clotting factor VIII using retroviral vectors [36, 37]. However, MSC-secreted factor VIII induced anti-factor VIII neutralizing antibodies quickly after transplantation in immunocompetent mice [37].

Since MSCs are also known as osteoblast progenitors, their applications in bone regeneration as drug and gene delivery carriers have been explored. Kim et al. developed a nanocarrier of bioactive glass loaded with genetic-modified MSCs overexpressing BMP2 [32]. An in vitro study shows that BMP2 was released in a sustained manner and subsequently, the rat MSCs expressed all bone-related genes within 2 weeks. Another recent study describes transduction of NEL-like protein 1 (NELL1) gene into human-induced pluripotent stem cell-derived MSCs (iPSC-MSCs) [33]. Mineral synthesis was increased by 81% in NELL1-iPSC-MSCs at 21 days in vitro. NELL1 overexpression can greatly enhance the osteogenic differentiation and mineral synthesis of iPSC-MSCs. However, due to the tumorigenesis risk of iPSCs, it is necessary to safe guard the purity of iPSC-MSCs before clinical application.

Conclusions and Perspectives

Based on the available MSC-related preclinical and clinical data, MSC-based therapies can be applied to a wide spectrum of clinical disorders. However, the nature of the illnesses and the specific targeted tissue for repair have to be pre-selected carefully and should be done under strict clinical trial setting. Use of MSCs as an adjunct to existing treatment regimen or utilization of genetically modified MSCs for specific protein delivery are attractive concepts but the actual clinical feasibility has to be investigated thoroughly. Some ongoing studies attempting to manipulate the genetic or epigenetic profile of MSCs for clinical application by using either chemicals or soluble factors are attractive ideas but remains to be proven. Galaderisi reviewed 493 MSC-based clinical trials in 2016. The top 3 fields are bone and cartilage disease (19.1%), neurological disease (17.8%), and cardiovascular diseases (14.8%) [102]. According to their records, promising therapeutic outcomes with recipient tolerability of MSC were observed in completed trials. However, recent studies also show both cancer-promoting and anticancer potentials of MSCs [103]. The role of MSCs in tumor progression and metastasis remains to be further investigated. For safe and effective therapy, questions remain as to the best MSCs to be used according to their sources, passage number, dosage, culture condition, etc. They have to be clarified in comparative studies. The current limitations of MSCs in clinical applications are their heterogeneity in the culture system and their finite ex vivo expansion capacity. The use of iPS cell-derived MSCs or immortalized MSCs are two possible solutions to overcome such limitations.



Many thanks to Dr. Hang Liu, Dr. Amy Bun Tsoi and Dr. Chong Gao for the assistance with the revisions. Works are supported by the donation from Providence Foundation Limited, Hong Kong.

Compliance with Ethical Standards

Conflict of Interest

Ruixia Deng, Anna Hing Yee Law, Jiangang Shen and Godfrey Chi-Fung Chan declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3(4):393–403.PubMedGoogle Scholar
  2. 2.
    Dominici M, le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Zuo W, Xie B, Li C, Yan Y, Zhang Y, Liu W, Huang J, Chen D. The Clinical Applications of Endometrial Mesenchymal Stem Cells. Biopreserv Biobank. 2018; 16(2):158-164.PubMedGoogle Scholar
  4. 4.
    Farini A, et al. Clinical applications of mesenchymal stem cells in chronic diseases. Stem Cells Int. 2014;2014:306573.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Kim N, Cho SG. Clinical applications of mesenchymal stem cells. Korean J Intern Med. 2013;28(4):387–402.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Choi SA, Yun JW, Joo KM, Lee JY, Kwak PA, Lee YE, et al. Preclinical biosafety evaluation of genetically modified human adipose tissue-derived mesenchymal stem cells for clinical applications to brainstem glioma. Stem Cells Dev. 2016;25(12):897–908.PubMedGoogle Scholar
  7. 7.
    Robles JD, Liu YP, Cao J, Xiang Z, Cai Y, Manio M, et al. Immunosuppressive mechanisms of human bone marrow derived mesenchymal stromal cells in BALB/c host graft versus host disease murine models. Exp Hematol Oncol. 2015;4:13.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Tso GH, Law HK, Tu W, Chan GC, Lau YL. Phagocytosis of apoptotic cells modulates mesenchymal stem cells osteogenic differentiation to enhance IL-17 and RANKL expression on CD4+ T cells. Stem Cells. 2010;28(5):939–54.Google Scholar
  9. 9.
    •• Ni K, Liu M, Zheng J, Wen L, Chen Q, Xiang Z, Lam KT, Liu Y, Chan GC, Lau YL et al. PD-1/PD-L1 Pathway Mediates the Alleviation of Pulmonary Fibrosis by Human Mesenchymal Stem Cells in Humanized Mice. Am J Respir Cell Mol Biol. 2018;58(6):684-695. (First article to show the benefit of mesenchymal stem cells in treating pulmonary fibrosis model. It also used mice with humanized immune system so the underlying mechanisms can be studied accurately.)PubMedGoogle Scholar
  10. 10.
    Wang D, Huang S, Yuan X, Liang J, Xu R, Yao G, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2017;14(5):423–31.PubMedGoogle Scholar
  11. 11.
    Chen C, Liang J, Yao G, Chen H, Shi B, Zhang Z, et al. Mesenchymal stem cells upregulate Treg cells via sHLA-G in SLE patients. Int Immunopharmacol. 2017;44:234–41.PubMedGoogle Scholar
  12. 12.
    Chen J, et al. Umbilical cord-derived mesenchymal stem cells suppress autophagy of T cells in patients with systemic lupus erythematosus via transfer of mitochondria. Stem Cells Int. 2016;2016:4062789.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Lee HK, Kim HS, Kim JS, Kim YG, Park KH, Lee JH, et al. CCL2 deficient mesenchymal stem cells fail to establish long-lasting contact with T cells and no longer ameliorate lupus symptoms. Sci Rep. 2017;7:41258.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Chen QQ, Yan L, Wang CZ, Wang WH, Shi H, Su BB, et al. Mesenchymal stem cells alleviate TNBS-induced colitis by modulating inflammatory and autoimmune responses. World J Gastroenterol. 2013;19(29):4702–17.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Mao F, Wu Y, Tang X, Wang J, Pan Z, Zhang P, et al. Human umbilical cord mesenchymal stem cells alleviate inflammatory bowel disease through the regulation of 15-LOX-1 in macrophages. Biotechnol Lett. 2017;39(6):929–38.PubMedGoogle Scholar
  16. 16.
    • de Aguiar CF, Castoldi A, Andrade-Oliveira V, Ignacio A, da Cunha FF, Felizardo RJF, Bassi EJ, Camara NOS, de Almeida DC. Mesenchymal stromal cells modulate gut inflammation in experimental colitis. Inflammopharmacology 2018;26(1):251-260. (This article showed adipose tissue-derived MSCs modulated overall gut inflammation in experimental colitis. This finding proved MSCs from different sources presenting similar immune modulating effects in vivo.)Google Scholar
  17. 17.
    Qiu Y, Guo J, Mao R, Chao K, Chen BL, He Y, et al. TLR3 preconditioning enhances the therapeutic efficacy of umbilical cord mesenchymal stem cells in TNBS-induced colitis via the TLR3-Jagged-1-Notch-1 pathway. Mucosal Immunol. 2017;10(3):727–42.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Fuenzalida P, Kurte M, Fernández-O'ryan C, Ibañez C, Gauthier-Abeliuk M, Vega-Letter AM, et al. Toll-like receptor 3 pre-conditioning increases the therapeutic efficacy of umbilical cord mesenchymal stromal cells in a dextran sulfate sodium-induced colitis model. Cytotherapy. 2016;18(5):630–41.PubMedGoogle Scholar
  19. 19.
    Mahfouz MM, Abdelsalam RM, Masoud MA, Mansour HA, Ahmed-Farid OA, Kenawy SA. The neuroprotective effect of mesenchymal stem cells on an experimentally induced model for multiple sclerosis in mice. J Biochem Mol Toxicol 2017;31(9).Google Scholar
  20. 20.
    Jiang H, Zhang Y, Tian K, Wang B, Han S. Amelioration of experimental autoimmune encephalomyelitis through transplantation of placental derived mesenchymal stem cells. Sci Rep. 2017;7:41837.PubMedPubMedCentralGoogle Scholar
  21. 21.
    • Wang X, Kimbrel EA, Ijichi K, Paul D, Lazorchak AS, Chu J, et al. Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Reports. 2014;3(1):115–30. (This article showed MSCs induced from human ES presenting protecting effect against neuronal demyelination in EAE mouse model. It showed a novel method to expand the functional MSCs ex vivo.)Google Scholar
  22. 22.
    Anderson P, et al. Allogeneic adipose-derived mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by regulating self-reactive T cell responses and dendritic cell function. Stem Cells Int. 2017;2017:2389753.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Tafreshi AP, Payne N, Sun G, Sylvain A, Schulze K, Bernard C. Inactive GSK3beta is disturbed in the spinal cord during experimental autoimmune encephalomyelitis, but rescued by stem cell therapy. Neuroscience. 2014;277:498–505.PubMedGoogle Scholar
  24. 24.
    • Dang S, Xu H, Xu C, Cai W, Li Q, Cheng Y, et al. Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmune encephalomyelitis. Autophagy. 2014;10(7):1301–15. (It described the underlying mechanism of MSCs treatment for MS.)PubMedPubMedCentralGoogle Scholar
  25. 25.
    Wang D, Li SP, Fu JS, Bai L, Guo L. Resveratrol augments therapeutic efficiency of mouse bone marrow mesenchymal stem cell-based therapy in experimental autoimmune encephalomyelitis. Int J Dev Neurosci. 2016;49:60–6.PubMedGoogle Scholar
  26. 26.
    Khezri S, Abtahi Froushani SM, Shahmoradi M. Nicotine Augments the Beneficial Effects of Mesenchymal Stem Cell-based Therapy in Rat Model of Multiple Sclerosis. Immunol Invest 2018;47(2):113-124.PubMedGoogle Scholar
  27. 27.
    Xia X, Chiu PWY, Lam PK, Chin WC, Ng EKW, Lau JYW. Secretome from hypoxia-conditioned adipose-derived mesenchymal stem cells promotes the healing of gastric mucosal injury in a rodent model. Biochim Biophys Acta. 2018;1864(1):178–88.Google Scholar
  28. 28.
    Ke F, Zhang L, Liu Z, Yan S, Xu Z, Bai J, et al. Soluble tumor necrosis factor receptor 1 released by skin-derived mesenchymal stem cells is critical for inhibiting Th17 cell differentiation. Stem Cells Transl Med. 2016;5(3):301–13.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Lotfinia M, Kadivar M, Piryaei A, Pournasr B, Sardari S, Sodeifi N, et al. Effect of secreted molecules of human embryonic stem cell-derived mesenchymal stem cells on acute hepatic failure model. Stem Cells Dev. 2016;25(24):1898–908.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Wang L, Gu Z, Zhao X, Yang N, Wang F, Deng A, et al. Extracellular vesicles released from human umbilical cord-derived mesenchymal stromal cells prevent life-threatening acute graft-versus-host disease in a mouse model of allogeneic hematopoietic stem cell transplantation. Stem Cells Dev. 2016;25(24):1874–83.PubMedGoogle Scholar
  31. 31.
    Huang JH, Yin XM, Xu Y, Xu CC, Lin X, Ye FB, et al. Systemic administration of exosomes released from mesenchymal stromal cells attenuates apoptosis, inflammation, and promotes angiogenesis after spinal cord injury in rats. J Neurotrauma. 2017;34(24):3388–96.PubMedGoogle Scholar
  32. 32.
    Kim TH, Singh RK, Kang MS, Kim JH, Kim HW. Gene delivery nanocarriers of bioactive glass with unique potential to load BMP2 plasmid DNA and to internalize into mesenchymal stem cells for osteogenesis and bone regeneration. Nanoscale. 2016;8(15):8300–11.PubMedGoogle Scholar
  33. 33.
    Liu J, Chen W, Zhao Z, Xu HHK. Effect of NELL1 gene overexpression in iPSC-MSCs seeded on calcium phosphate cement. Acta Biomater. 2014;10(12):5128–38.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Sen S, Domingues CC, Rouphael C, Chou C, Kim C, Yadava N. Genetic modification of human mesenchymal stem cells helps to reduce adiposity and improve glucose tolerance in an obese diabetic mouse model. Stem Cell Res Ther. 2015;6:242.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Evans GL, Morgan RA. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci U S A. 1998;95(10):5734–9.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Doering CB. Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia. Methods Mol Biol. 2008;433:203–12.PubMedGoogle Scholar
  37. 37.
    Gangadharan B, Parker ET, Ide LM, Spencer HT, Doering CB. High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Blood. 2006;107(10):3859–64.PubMedGoogle Scholar
  38. 38.
    Zhou YF, Yang XJ, Li HX, Han LH, Jiang WP. Genetically-engineered mesenchymal stem cells transfected with human HCN1 gene to create cardiac pacemaker cells. J Int Med Res. 2013;41(5):1570–6.PubMedGoogle Scholar
  39. 39.
    McGinley LM, McMahon J, Stocca A, Duffy A, Flynn A, O'Toole D, et al. Mesenchymal stem cell survival in the infarcted heart is enhanced by lentivirus vector-mediated heat shock protein 27 expression. Hum Gene Ther. 2013;24(10):840–51.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Razban V, Lotfi AS, Soleimani M, Ahmadi H, Massumi M, Khajeh S, et al. HIF-1alpha overexpression induces angiogenesis in mesenchymal stem cells. Biores Open Access. 2012;1(4):174–83.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Zhou YF, Yang XJ, Li HX, Han LH, Jiang WP. Mesenchymal stem cells transfected with HCN2 genes by LentiV can be modified to be cardiac pacemaker cells. Med Hypotheses. 2007;69(5):1093–7.PubMedGoogle Scholar
  42. 42.
    Fan L, Lin C, Zhuo S, Chen L, Liu N, Luo Y, et al. Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction. Eur J Heart Fail. 2009;11(11):1023–30.PubMedGoogle Scholar
  43. 43.
    Wang X, Zhao T, Huang W, Wang T, Qian J, Xu M, et al. Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells. 2009;27(12):3021–31.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Ahmed RP, et al. Sonic hedgehog gene delivery to the rodent heart promotes angiogenesis via iNOS/netrin-1/PKC pathway. PLoS One. 2010;5(1):e8576.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Wu XM, et al. Experimental study of rat mesenchymal stem cells transfected with sonic hedgehog gene. Zhonghua Yi Xue Za Zhi. 2012;92(10):705–8.PubMedGoogle Scholar
  46. 46.
    Xue X, et al. Bcl-xL genetic modification enhanced the therapeutic efficacy of mesenchymal stem cell transplantation in the treatment of heart infarction. Stem Cells Int. 2015;2015:176409.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Cho HM, Kim PH, Chang HK, Shen YM, Bonsra K, Kang BJ, et al. Targeted genome engineering to control VEGF expression in human umbilical cord blood-derived mesenchymal stem cells: potential implications for the treatment of myocardial infarction. Stem Cells Transl Med. 2017;6(3):1040–51.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Ishii M, Numaguchi Y, Okumura K, Kubota R, Ma X, Murakami R, et al. Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia. Atherosclerosis. 2009;206(1):109–18.PubMedGoogle Scholar
  49. 49.
    Duffy GP, D'Arcy S, Ahsan T, Nerem RM, O'Brien T, Barry F. Mesenchymal stem cells overexpressing ephrin-b2 rapidly adopt an early endothelial phenotype with simultaneous reduction of osteogenic potential. Tissue Eng A. 2010;16(9):2755–68.Google Scholar
  50. 50.
    Lu W, et al. Transplantation of rat mesenchymal stem cells overexpressing hypoxia-inducible factor 2alpha improves blood perfusion and arteriogenesis in a rat hindlimb ischemia model. Stem Cells Int. 2017;2017:3794817.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Chen S, Chen X, Wu X, Wei S, Han W, Lin J, et al. Hepatocyte growth factor-modified mesenchymal stem cells improve ischemia/reperfusion-induced acute lung injury in rats. Gene Ther. 2017;24(1):3–11.PubMedGoogle Scholar
  52. 52.
    Kolli N, Lu M, Maiti P, Rossignol J, Dunbar GL. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease. Int J Mol Sci 2017;18(4). PubMedCentralGoogle Scholar
  53. 53.
    Yu H, et al. Analgesia for neuropathic pain by dorsal root ganglion transplantation of genetically engineered mesenchymal stem cells: initial results. Mol Pain. 2015;11:5.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, et al. Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington’s disease. Behav Brain Res. 2010;214(2):193–200.PubMedGoogle Scholar
  55. 55.
    •• Pollock K, Dahlenburg H, Nelson H, Fink KD, Cary W, Hendrix K, et al. Human mesenchymal stem cells genetically engineered to overexpress brain-derived neurotrophic factor improve outcomes in Huntington’s disease mouse models. Mol Ther. 2016;24(5):965–77. (Significant improvement of HD in mouse model with BDNF trasduced human MSCs.)PubMedPubMedCentralGoogle Scholar
  56. 56.
    Deng P, Torrest A, Pollock K, Dahlenburg H, Annett G, Nolta JA, et al. Clinical trial perspective for adult and juvenile Huntington's disease using genetically-engineered mesenchymal stem cells. Neural Regen Res. 2016;11(5):702–5.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Bierlein De la Rosa M, et al. Transdifferentiation of brain-derived neurotrophic factor (BDNF)-secreting mesenchymal stem cells significantly enhance BDNF secretion and Schwann cell marker proteins. J Biosci Bioeng. 2017;124(5):572–82.PubMedGoogle Scholar
  58. 58.
    Tang H, Xiang Y, Jiang X, Ke Y, Xiao Z, Guo Y, et al. Dual expression of hTERT and VEGF prolongs life span and enhances angiogenic ability of aged BMSCs. Biochem Biophys Res Commun. 2013;440(4):502–8.PubMedGoogle Scholar
  59. 59.
    Son S, Liang MS, Lei P, Xue X, Furlani EP, Andreadis ST. Magnetofection mediated transient NANOG overexpression enhances proliferation and myogenic differentiation of human hair follicle derived mesenchymal stem cells. Bioconjug Chem. 2015;26(7):1314–27.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Kalimuthu S, et al. In vivo tracking of chemokine receptor CXCR4-engineered mesenchymal stem cell migration by optical molecular imaging. Stem Cells Int. 2017;2017:8085637.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Kuroki LM, et al. Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: an opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer. PLoS One. 2017;12(12):e0190125.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Hammer K, Kazcorowski A, Liu L, Behr M, Schemmer P, Herr I, et al. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells. Int J Cancer. 2015;137(4):978–90.PubMedGoogle Scholar
  63. 63.
    Balyasnikova IV, Franco-Gou R, Mathis JM, Lesniak MS. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. J Tissue Eng Regen Med. 2010;4(4):247–58.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Zhang J, Hou L, Wu X, Zhao D, Wang Z, Hu H, et al. Inhibitory effect of genetically engineered mesenchymal stem cells with apoptin on hepatoma cells in vitro and in vivo. Mol Cell Biochem. 2016;416(1–2):193–203.PubMedGoogle Scholar
  65. 65.
    Shahrokhi S, Daneshmandi S, Menaa F. Tumor necrosis factor-alpha/CD40 ligand-engineered mesenchymal stem cells greatly enhanced the antitumor immune response and lifespan in mice. Hum Gene Ther. 2014;25(3):240–53.PubMedGoogle Scholar
  66. 66.
    Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD, et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther. 2008;15(21):1446–53.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Liu TM, Wu YN, Guo XM, Hui JHP, Lee EH, Lim B. Effects of ectopic Nanog and Oct4 overexpression on mesenchymal stem cells. Stem Cells Dev. 2009;18(7):1013–22.PubMedGoogle Scholar
  68. 68.
    Hoare M, Greiser U, Schu S, Mashayekhi K, Aydogan E, Murphy M, et al. Enhanced lipoplex-mediated gene expression in mesenchymal stem cells using reiterated nuclear localization sequence peptides. J Gene Med. 2010;12(2):207–18.PubMedGoogle Scholar
  69. 69.
    Blum JS, Barry MA, Mikos AG, Jansen JA. In vivo evaluation of gene therapy vectors in ex vivo-derived marrow stromal cells for bone regeneration in a rat critical-size calvarial defect model. Hum Gene Ther. 2003;14(18):1689–701.PubMedGoogle Scholar
  70. 70.
    Zhang XY, la Russa VF, Bao L, Kolls J, Schwarzenberger P, Reiser J. Lentiviral vectors for sustained transgene expression in human bone marrow-derived stromal cells. Mol Ther. 2002;5(5 Pt 1):555–65.PubMedGoogle Scholar
  71. 71.
    Santos JL, et al. Non-viral gene delivery to mesenchymal stem cells: methods, strategies and application in bone tissue engineering and regeneration. Curr Gene Ther. 2011;11(1):46–57.PubMedGoogle Scholar
  72. 72.
    Shan L. Poly(N,N-dimethylacrylamide)-coated maghemite nanoparticles for labeling and tracking mesenchymal stem cells, in Molecular Imaging and Contrast Agent Database (MICAD). Bethesda: National Center for Biotechnology Information (US); 2004.Google Scholar
  73. 73.
    Shan L. Amine-modified silica-coated polyhedral superparamagnetic iron oxide nanoparticle-labeled rabbit bone marrow-derived mesenchymal stem cells, in Molecular Imaging and Contrast Agent Database (MICAD). Bethesda: National Center for Biotechnology Information (US); 2004.Google Scholar
  74. 74.
    Shan L. FluidMAG iron nanoparticle-labeled mesenchymal stem cells for tracking cell homing to tumors, in Molecular Imaging and Contrast Agent Database (MICAD). Bethesda: National Center for Biotechnology Information (US); 2004.Google Scholar
  75. 75.
    Stiehler M, Duch M, Mygind T, Li H, Ulrich-Vinther M, Modin C, et al. Optimizing viral and non-viral gene transfer methods for genetic modification of porcine mesenchymal stem cells. Adv Exp Med Biol. 2006;585:31–48.PubMedGoogle Scholar
  76. 76.
    Ikeda Y, Makino A, Matchett WE, Holditch SJ, Lu B, Dietz AB, et al. A novel intranuclear RNA vector system for long-term stem cell modification. Gene Ther. 2016;23(3):256–62.PubMedGoogle Scholar
  77. 77.
    Chicaybam L, et al. An efficient electroporation protocol for the genetic modification of mammalian cells. Front Bioeng Biotechnol. 2016;4:99.PubMedGoogle Scholar
  78. 78.
    Piao W, Wang H, Inoue M, Hasegawa M, Hamada H, Huang J. Transplantation of Sendai viral angiopoietin-1-modified mesenchymal stem cells for ischemic limb disease. Angiogenesis. 2010;13(3):203–10.PubMedGoogle Scholar
  79. 79.
    •• Park JS, Suryaprakash S, Lao YH, Leong KW. Engineering mesenchymal stem cells for regenerative medicine and drug delivery. Methods. 2015;84:3–16. (Detail descriptions of different vector construct for genetic modifications.)PubMedPubMedCentralGoogle Scholar
  80. 80.
    Kaczorowski A, Hammer K, Liu L, Villhauer S, Nwaeburu C, Fan P, et al. Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells. Oncotarget. 2016;7(8):9046–59.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Yuan X, Zhang Q, Li Z, Zhang X, Bao S, Fan D, et al. Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically. Cancer Lett. 2016;381(1):85–95.PubMedGoogle Scholar
  82. 82.
    Melen GJ, Franco-Luzón L, Ruano D, González-Murillo Á, Alfranca A, Casco F, et al. Influence of carrier cells on the clinical outcome of children with neuroblastoma treated with high dose of oncolytic adenovirus delivered in mesenchymal stem cells. Cancer Lett. 2016;371(2):161–70.PubMedGoogle Scholar
  83. 83.
    Du W, et al. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci U S A. 2017;114(30):E6157–65.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Farrell E, et al. vIL-10-overexpressing human MSCs modulate naive and activated T lymphocytes following induction of collagenase-induced osteoarthritis. Stem Cell Res Ther. 2016;7(1):74.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Nakajima M, Nito C, Sowa K, Suda S, Nishiyama Y, Nakamura-Takahashi A, et al. Mesenchymal stem cells overexpressing interleukin-10 promote neuroprotection in experimental acute ischemic stroke. Mol Ther Methods Clin Dev. 2017;6:102–11.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Mohammadzadeh A, Pourfathollah AA, Shahrokhi S, Fallah A, Tahoori MT, Amari A, et al. Evaluation of AD-MSC (adipose-derived mesenchymal stem cells) as a vehicle for IFN-beta delivery in experimental autoimmune encephalomyelitis. Clin Immunol. 2016;169:98–106.PubMedGoogle Scholar
  87. 87.
    • Marin-Banasco C, et al. Gene therapy with mesenchymal stem cells expressing IFN-ss ameliorates neuroinflammation in experimental models of multiple sclerosis. Br J Pharmacol. 2017;174(3):238–53. (Alternative MSCs treatment for MS with genetic modification.)Google Scholar
  88. 88.
    Liao W, Pham V, Liu L, Riazifar M, Pone EJ, Zhang SX, et al. Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis. Biomaterials. 2016;77:87–97.PubMedGoogle Scholar
  89. 89.
    Zhao LX, Zhang J, Cao F, Meng L, Wang DM, Li YH, et al. Modification of the brain-derived neurotrophic factor gene: a portal to transform mesenchymal stem cells into advantageous engineering cells for neuroregeneration and neuroprotection. Exp Neurol. 2004;190(2):396–406.PubMedGoogle Scholar
  90. 90.
    Golpanian S, Wolf A, Hatzistergos KE, Hare JM. Rebuilding the damaged heart: mesenchymal stem cells, cell-based therapy, and engineered heart tissue. Physiol Rev. 2016;96(3):1127–68.PubMedGoogle Scholar
  91. 91.
    Guo J, et al. Insulin-like growth factor 1 improves the efficacy of mesenchymal stem cells transplantation in a rat model of myocardial infarction. J Biomed Sci. 2008;15(1):89–97.PubMedGoogle Scholar
  92. 92.
    Hahn JY, Cho HJ, Kang HJ, Kim TS, Kim MH, Chung JH, et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol. 2008;51(9):933–43.PubMedGoogle Scholar
  93. 93.
    Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311(1):62–73.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Hatzistergos KE, Quevedo H, Oskouei BN, Hu Q, Feigenbaum GS, Margitich IS, et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res. 2010;107(7):913–22.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Bian L, Guo ZK, Wang HX, Wang JS, Wang H, Li QF, et al. In vitro and in vivo immunosuppressive characteristics of hepatocyte growth factor-modified murine mesenchymal stem cells. In Vivo. 2009;23(1):21–7.PubMedGoogle Scholar
  96. 96.
    ** Shi Y, du L, Lin L, Wang Y. Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov. 2017;16(1):35–52. (A recent and excellent review on genetic modified MSCs in cancer treatments.)Google Scholar
  97. 97.
    Lazennec G, Lam PY. Recent discoveries concerning the tumor—mesenchymal stem cell interactions. Biochim Biophys Acta. 2016;1866(2):290–9.PubMedGoogle Scholar
  98. 98.
    Sage EK, Thakrar RM, Janes SM. Genetically modified mesenchymal stromal cells in cancer therapy. Cytotherapy. 2016;18(11):1435–45.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Yu JL, Deng R, Chung SK, Chan GCF. Epac activation regulates human mesenchymal stem cells migration and adhesion. Stem Cells. 2016;34(4):948–59.PubMedGoogle Scholar
  100. 100.
    Ma M, Ye JY, Deng R, Dee CM, Chan GCF. Mesenchymal stromal cells may enhance metastasis of neuroblastoma via SDF-1/CXCR4 and SDF-1/CXCR7 signaling. Cancer Lett. 2011;312(1):1–10.PubMedGoogle Scholar
  101. 101.
    Zhang Y, et al. Genetic modification of bone marrow mesenchymal stem cells with human CXCR4 gene and migration in vitro. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2009;26(3):595–600.PubMedGoogle Scholar
  102. 102.
    Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829–48.PubMedGoogle Scholar
  103. 103.
    Lee HY, Hong IS. Double-edged sword of mesenchymal stem cells: cancer-promoting versus therapeutic potential. Cancer Sci. 2017;108(10):1939–46.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Ruixia Deng
    • 1
    • 2
  • Anna Hing Yee Law
    • 1
  • Jiangang Shen
    • 2
  • Godfrey Chi-Fung Chan
    • 1
    • 3
    Email author
  1. 1.Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, 7/F, Laboratory BuildingThe University of Hong KongPokfulamHong Kong
  2. 2.School of Chinese Medicine, Li Ka Shing Faculty of MedicineThe University of Hong KongPokfulamHong Kong
  3. 3.Department of Paediatrics and Adolescent MedicineQueen Mary HospitalHong KongHong Kong

Personalised recommendations